Sep 9, 2021
In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines.
- Welcome to another exciting episode of Oncology Overdrive :13
- About Baldo :17
- The interview 1:20
- Tell me about your journey 1:38
- Did you question your decision to leave clinical practice for an entrepreneurial venture? 2:36
- What does Adaptive Biotechnologies do? 3:43
- What is Minimal Residual Disease (MRD) testing and how is it used? 4:27
- Are you looking only at hematologic malignancies? 5:35
- How are experts using MRD testing in clinical practice? 6:31
- Why do you think MRD testing is important in treating cancers? 7:24
- Is Adaptive working on drug discovery and development related to MRD testing? 9:20
- Personalized care and how real life feels like science fiction 12:02
- Doing what’s best for the patient 15:33
- Tell me about T-cell receptor profiling 18:02
- Tell me about neo-antigen-based therapy 21:10
- Are these types of technologies available outside of large, academic institutions? 22:49
- Has COVID impacted the way you and your team think about implementing therapies and innovation? 25:03
- Do you think what we’ve learned over the last year will help with the creation of future cancer vaccines? 29:59
- If we spoke again in 10 years, what would you hope to have done? 31:25
- Baldo’s take-home message 37:42
- Where to find Baldo 38:57
Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies.
We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on LinkedIn, via email at lbaldo@adaptivebiotech.com and at www.adaptivebiotech.com.
Disclosures: Baldo is chief medical officer of Adaptive Biotechnologies. Jain reports she is a paid freelance writer for Lippincott.